NEW YORK, Jan. 29-LI-COR Biosciences and BD Biosciences will jointly market an infrared antibody-based imaging system for cell signaling pathway analysis, the two companies said today.
In the cooperative effort, BD's Pharmigen division will supply antibodies designed for use with LI-COR's Odyssey Infrared Imaging System.
BD Biosciences Pharmigen has a license to LI-COR's IRDye800CW, and will commercialize antibodies conjugated to this dye.
These two products will allow researchers interested in cell signaling to analyze more than one target molecule at a time. LI-COR says that its infrared imaging system can detect and quantify as little as one picogram of protein in Western blots.
LI-COR, which makes infrared labeling systems for sequencing, genotyping, and proteomics, is based in Lincoln, Neb. BD Biosciences is a business division of Becton, Dickinson and Company.
For further information, see the press release.